Scientists at the Universities of Brussels and Louvain in collaboration with UCB Pharma in Belgium have studied the solvent-mediated transformation of one polymorphic form of etiracetam ( the racemic intermediate in the synthesis of levetiracetam, marketed as Keppra by UCB Pharma) to the favoured form I prior to isolation of this desired form from methanol. (OPRD, 2012, 16, 49-56).